Highly efficient induction of protective immunity by a vaccinia virus vector defective in late gene expression

Journal of Virology

Volumn 73, Issue 6, 1999, Pages 4536-4542

  Holzer, G W ^a   Remp, G ^a   Antoine, G ^a   Pfleiderer, M ^a   Enzersberger, O M ^a   Emsenhuber, W ^a   Hammerle T ^a   Gruber, F ^a   Urban, C ^a   Falkner, F G ^a   Dorner, F ^a  

^a BAXTER INNOVATIONS GMBH   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

LIVE VACCINE; NEUTRALIZING ANTIBODY; URACIL DNA GLYCOSYLTRANSFERASE; VIRUS VECTOR;

ANTIBODY TITER; ANTIGEN EXPRESSION; ARTICLE; CANCER IMMUNOTHERAPY; DNA REPLICATION; GENE EXPRESSION SYSTEM; IMMUNE RESPONSE; NONHUMAN; PRIORITY JOURNAL; VACCINIA VIRUS; VIRUS GENE;

EID: 0032996121     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/jvi.73.6.4536-4542.1999     Document Type: Article

References (34)

1. Antoine, G., F. Scheiflinger, F. Dorner, and F. G. Falkner. 1998. Genomic sequence of the modified vaccinia Ankara (MVA) strain: comparison with other orthopoxviruses. Virology 244:365-396.
2. Bronte, V., M. W. Carroll, T. J. Goletz, M. Wang, W. W. Overwijk, F. Marincola, S. A. Rosenberg, B. Moss, and N. P. Restifo. 1997. Antigen expression by dendritic cells correlates with the therapeutic effectiveness of a model recombinant poxvirus tumor vaccine. Proc. Natl. Acad. Sci. USA 94:3183-3188.
3. Chakrabarti, S., K. Brechling, and B. Moss. 1985. Vaccinia virus expression vector: coexpression of beta-galactosidase provides visual screening of re-combinant virus plaques. Mol. Cell. Biol. 5:3403-3409.
4. Chakrabarti, S., J. R. Sisler, and B. Moss. 1997. Compact, synthetic, vaccinia virus early/late promoter for protein expression. BioTechniques 23:1094-1097.
5. Coupar, B. E., M. E. Andrew, G. W. Both, and D. B. Boyle. 1986. Temporal regulation of influenza hemagglutinin expression in vaccinia virus recombinants and effects on the immune response. Eur. J. Immunol. 16:1479-1487.
6. Dmitriev, I. P., A. A. Khromykh, G. M. Ignatyev, M. N. Gainullina, V. A. Ageenko, S. A. Dryga, M. S. Vorobyeva, and L. S. Sandakhchiev. 1996. Immunization with recombinant vaccinia viruses expressing structural and part of the nonstructural region of tick-borne encephalitis virus cDNA protect mice against lethal encephalitis. J. Biotechnol. 44:97-103.
7. Earl, P. L., A. W. Hugin, and B. Moss. 1990. Removal of cryptic poxvirus transcription termination signals from the human immunodeficiency virus type 1 envelope gene enhances expression and immunogenicity of a recombinanl vaccinia virus. J. Virol. 64:2448-2451.
8. Falkner, F. G., and B. Moss. 1988. Escherichia coli gpt gene provides dominant selection for vaccinia virus open reading frame expression vectors. J. Virol. 62:1849-1854.
9. Falkner, F. G., and B. Moss. 1990. Transient dominant selection of recombinant vaccinia viruses. J. Virol. 64:3108-3111.
10. Goebel, S. J., G. P. Johnson, M. E. Perkus, S. W. Davis, J. P. Winslow, and E. Paoletti. 1990. The complete DNA sequence of vaccinia virus. Virology 179:247-266, 517-563.
11. Hämmerle, T., M. Himmelspach, F. Dorner, and F. G. Falkner. 1997. A sensitive PCR assay system for the quantitation of viral genome equivalents: human immunodeficiency virus type 1 (HIV-1) and hepatitis virus (HBV). Arch. Virol. 142:1297-1306.
12. Heinz, F. X., and C. W. Mandl. 1993. The molecular biology of tick-borne encephalitis virus. APMIS 101:735-745. (Review.)
13. Holzer, G. 1997. Ph.D. thesis. Universität für Bodenkultur, Vienna, Austria.
14. Holzer, G. W., and F. G. Falkner. 1997. Construction of a vaccinia virus deficient in the essential DNA repair enzyme uracil DNA glycosylase by a complementing cell line. J. Virol. 71:4997-5002.
15. Holzer, G. W., W. Gritschenberger, J. A. Mayrhofer, V. Wieser, F. Dorner, and F. G. Falkner. 1998. Dominant host range selection of vaccinia recombinants by rescue of an essential gene. Virology 249:160-166.
16. Jacobs, S. C., J. R. Stephenson, and G. W. G. Wilkinson. 1994. Protection elicited by a replication-defective adenovirus vector expressing the tick-borne encephalitis virus non-structural glycoprotein NS1. J. Gen. Virol. 75:2399-2402.
17. Joklik, W. K. 1962. The purification of four strains of poxvirus. Virology 18:9-18.
18. Kaerber, G. 1931. Beitrag zur kollektiven Behandlung pharmakologischer Reihenversuche. Arch. Exp. Pathol. Pharmakol. 162:480-483.
19. Mackett, M., G. L. Smith, and B. Moss. 1982. Vaccinia virus: a selectable eukaryotic cloning and expression vector. Proc. Natl. Acad. Sci. USA 79: 7415-7419.
20. Mandl, C. W., F. X. Heinz, and C. Kunz. 1988. Sequence of the structural proteins of tick-borne encephalitis virus (Western subtype) and comparative analysis with other flaviviruses. Virology 166:197-205.
21. Mayr, A., H. Stickl, H. K. Müller, K. Danner, and H. Singer. 1978. The smallpox vaccination strain MVA: marker, genetic structure, experience gained with the parenteral vaccination and behavior in organisms with a debilitated defence mechanism. Zentbl. Bakteriol. Hyg. Abt. 1 Orig. Reihe B 167:375-390.
22. Miller, J. H. 1972. Experiments in molecular genetics. Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y.
23. Millns, A. K., M. S. Carpenter, and A. M. DeLange. 1994. The vaccinia virus-encoded uracil DNA glycosylase has an essential role in viral DNA replication. Virology 198:504-513.
24. Moss, B. 1996. Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety. Proc. Natl. Acad. Sci. USA 93:11341-11348.
25. Paoletli, E. 1996. Applications of pox virus vectors to vaccination: an update. Proc. Natl. Acad. Sci. USA 93:11349-11353.
26. Pfleiderer, M., F. G. Falkner, and F. Dorner. 1995. Requirements for optimal expression of secreted and non-secreted recombinant proteins in vaccinia virus systems. Protein Expression Purif. 6:559-569.
27. Scheiflinger, F., F. Dorner, and F. G. Falkner. 1998. Transient marker stabilisation: a general procedure to construct marker-free recombinant vaccinia virus. Arch. Virol. 143:467-474.
28. Somogyi, P., J. Frazier, and M. A. Skinner. 1993. Fowlpox virus host range restriction: gene expression, DNA replication, and morphogenesis in non-permissive mammalian cells. Virology 197:439-444.
29. Sutter, G., and B. Moss. 1992. Nonreplicating vaccinia vector efficiently expresses recombinant genes. Proc. Natl. Acad. Sci. USA 89:10847-10851.
30. Tartaglia, J., M. E. Perkus, J. Taylor. E. K. Norton, J. C. Audonnet, W. I. Cox, S. W. Davis, J. van der Hoeven, B. Meignier, M. Riviere, B. Languet, and E. Paoletti. 1992. NYVAC: a highly attenuated strain of vaccinia virus. Virology 188:217-232.
31. Taylor, J., and E. Paoletti. 1988. Fowlpox virus as a vector in non-avian species. Vaccine 6:466-468.
32. Venugopal, K., and E. A. Gould. 1994. Towards a new generation of flavivirus vaccines. Vaccine 12:966-975.
33. Wachsman, M., L. Aurelian, J. C. Hunter, M. E. Perkus, and E. Paoletti. 1988. Expression of herpes simplex virus glycoprotein D on antigen presenting cells infected with vaccinia recombinants and protective immunity. Biosci. Rep. 8:323-334.
34. Yuen, L., and B. Moss. 1987. Oligonucleotide sequence signaling transcriptional termination of vaccinia virus early genes. Proc. Natl. Acad. Sci. USA 84:6417-6421.